Browsing by Author "Dramburg, S"

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    Patient-centered digital biomarkers for allergic respiratory diseases and asthma: The ARIA-EAACI approach - ARIA-EAACI Task Force Report
    Bousquet, J; Shamji, MH; Anto, JM; Schünemann, HJ; Canonica, GW; Jutel, M; Del Giacco, S; Zuberbier, T; Pfaar, O; Fonseca, JA; Sousa-Pinto, B; Klimek, L; Czarlewski, W; Bedbrook, A; Amaral, R; Ansotegui, IJ; Bosnic-Anticevich, S; Braido, F; Loureiro, CC; Gemicioglu, B; Haahtela, T; Kulus, M; Kuna, P; Kupczyk, M; Matricardi, PM; Regateiro, FS; Samolinski, B; Sofiev, M; Toppila-Salmi, S; Valiulis, A; Ventura, MT; Barbara, C; Bergmann, KC; Bewick, M; Blain, H; Bonini, M; Boulet, LP; Bourret, R; Brusselle, G; Brussino, L; Buhl, R; Cardona, V; Casale, T; Cecchi, L; Charpin, D; Cherrez-Ojeda, I; Chu, DK; Cingi, C; Costa, EM; Cruz, AA; Devillier, P; Dramburg, S; Fokkens, WJ; Gotua, M; Heffler, E; Ispayeva, Z; Ivancevich, JC; Joos, G; Kaidashev, I; Kraxner, H; Kvedariene, V; Larenas-Linnemann, DE; Laune, D; Lourenço, O; Louis, R; Makela, M; Makris, M; Maurer, M; Melen, E; Micheli, Y; Morais-Almeida, M; Mullol, J; Niedoszytko, M; O'Hehir, R; Okamoto, Y; Olze, H; Papadopoulos, NG; Papi, A; Patella, V; Pétré, B; Pham-Thi, N; Puggioni, F; Quirce, S; Roche, N; Rouadi, PW; Sa-Sousa, A; Sagara, H; Sastre, J; Scichilone, N; Sheikh, A; Sova, M; Ulrik, CS; Taborda-Barata, L; Todo-Bom, A; Torres, MJ; Tsiligianni, I; Usmani, OS; Valovirta, E; Vasankari, T; Vieira, RJ; Wallace, D; Waserman, S; Zidarn, M; Yorgancioglu, A; Zhang, L; Chivato, T; Ollert, M
    Biomarkers for the diagnosis, treatment and follow-up of patients with rhinitis and/or asthma are urgently needed. Although some biologic biomarkers exist in specialist care for asthma, they cannot be largely used in primary care. There are no validated biomarkers in rhinitis or allergen immunotherapy (AIT) that can be used in clinical practice. The digital transformation of health and health care (including mHealth) places the patient at the center of the health system and is likely to optimize the practice of allergy. Allergic Rhinitis and its Impact on Asthma (ARIA) and EAACI (European Academy of Allergy and Clinical Immunology) developed a Task Force aimed at proposing patient-reported outcome measures (PROMs) as digital biomarkers that can be easily used for different purposes in rhinitis and asthma. It first defined control digital biomarkers that should make a bridge between clinical practice, randomized controlled trials, observational real-life studies and allergen challenges. Using the MASK-air app as a model, a daily electronic combined symptom-medication score for allergic diseases (CSMS) or for asthma (e-DASTHMA), combined with a monthly control questionnaire, was embedded in a strategy similar to the diabetes approach for disease control. To mimic real-life, it secondly proposed quality-of-life digital biomarkers including daily EQ-5D visual analogue scales and the bi-weekly RhinAsthma Patient Perspective (RAAP). The potential implications for the management of allergic respiratory diseases were proposed.
  • No Thumbnail Available
    Item
    COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper
    Pfaar, O; Klimek, L; Jutel, M; Akdis, CA; Bousquet, J; Breiteneder, H; Chinthrajah, S; Diamant, Z; Eiwegger, T; Fokkens, WJ; Fritsch, HW; Nadeau, KC; O'Hehir, RE; O'Mahony, L; Rief, W; Sampath, V; Schedlowski, M; Torres, MJ; Traidl-Hoffmann, C; Wang, DY; Zhang, L; Bonini, M; Brehler, R; Brough, HA; Chivato, T; Del Giacco, SR; Dramburg, S; Gawlik, R; Gelincik, A; Hoffmann-Sommergruber, K; Hox, V; Knol, EF; Lauerma, A; Matricardi, PM; Mortz, CG; Ollert, M; Palomares, O; Riggioni, C; Schwarze, J; Skypala, I; Untersmayr, E; Walusiak-Skorupa, J; Ansotegui, IJ; Bachert, C; Bedbrook, A; Bosnic-Anticevich, S; Brussino, L; Canonica, GW; Cardona, V; Carreiro-Martins, P; Cruz, AA; Czarlewski, W; Fonseca, JA; Gotua, M; Haahtela, T; Ivancevich, JC; Kuna, P; Kvedariene, V; Larenas-Linnemann, DE; Latiff, AHA; Mäkelä, M; Morais-Almeida, M; Mullol, J; Naclerio, R; Ohta, K; Okamoto, Y; Onorato, GL; Papadopoulos, NG; Patella, V; Regateiro, FS; Samolinski, B; Suppli Ulrik, C; Toppila-Salmi, S; Valiulis, A; Ventura, MT; Yorgancioglu, A; Zuberbier, T; Agache, I
    BackgroundThe coronavirus disease 2019 (COVID-19) has evolved into a pandemic infectious disease transmitted by the severe acute respiratory syndrome coronavirus (SARS-CoV-2). Allergists and other healthcare providers (HCPs) in the field of allergies and associated airway diseases are on the front line, taking care of patients potentially infected with SARS-CoV-2. Hence, strategies and practices to minimize risks of infection for both HCPs and treated patients have to be developed and followed by allergy clinics. MethodThe scientific information on COVID-19 was analysed by a literature search in MEDLINE, PubMed, the National and International Guidelines from the European Academy of Allergy and Clinical Immunology (EAACI), the Cochrane Library, and the internet. ResultsBased on the diagnostic and treatment standards developed by EAACI, on international information regarding COVID-19, on guidelines of the World Health Organization (WHO) and other international organizations, and on previous experience, a panel of experts including clinicians, psychologists, IT experts, and basic scientists along with EAACI and the Allergic Rhinitis and its Impact on Asthma (ARIA) initiative have developed recommendations for the optimal management of allergy clinics during the current COVID-19 pandemic. These recommendations are grouped into nine sections on different relevant aspects for the care of patients with allergies. ConclusionsThis international Position Paper provides recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients while ensuring the necessary safety measures in the current COVID-19 pandemic.
  • No Thumbnail Available
    Item
    Mobile Technology in Allergic Rhinitis: Evolution in Management or Revolution in Health and Care?
    Bousquet, J; Ansotegui, IJ; Anto, JM; Arnavielhe, S; Bachert, C; Basagaña, X; Bédard, A; Bedbrook, A; Bonini, M; Bosnic-Anticevich, S; Braido, F; Cardona, V; Czarlewski, W; Cruz, AA; Demoly, P; De Vries, G; Dramburg, S; Mathieu-Dupas, E; Erhola, M; Fokkens, WJ; Fonseca, JA; Haahtela, T; Hellings, PW; Illario, M; Ivancevich, JC; Jormanainen, V; Klimek, L; Kuna, P; Kvedariene, V; Laune, D; Larenas-Linnemann, D; Lourenço, O; Onorato, GL; Matricardi, PM; Melén, E; Mullol, J; Papadopoulos, NG; Pfaar, O; Pham-Thi, N; Sheikh, A; Tan, R; To, T; Tomazic, PV; Toppila-Salmi, S; Tripodi, S; Wallace, D; Valiulis, A; van Eerd, M; Ventura, MT; Yorgancioglu, A; Zuberbier, T
    Smart devices and Internet-based applications (apps) are largely used in allergic rhinitis and may help to address some unmet needs. However, these new tools need to first of all be tested for privacy rules, acceptability, usability, and cost-effectiveness. Second, they should be evaluated in the frame of the digital transformation of health, their impact on health care delivery, and health outcomes. This review (1) summarizes some existing mobile health apps for allergic rhinitis and reviews those in which testing has been published, (2) discusses apps that include risk factors of allergic rhinitis, (3) examines the impact of mobile health apps in phenotype discovery, (4) provides real-world evidence for care pathways, and finally (5) discusses mobile health tools enabling the digital transformation of health and care, empowering citizens, and building a healthier society. (C) 2019 American Academy of Allergy, Asthma & Immunology
  • No Thumbnail Available
    Item
    Development and validation of combined symptom-medication scores for allergic rhinitis*
    Sousa-Pinto, B; Azevedo, LF; Jutel, M; Agache, I; Canonica, GW; Czarlewski, W; Papadopoulos, NG; Bergmann, KC; Devillier, P; Laune, D; Klimek, L; Anto, A; Anto, JM; Eklund, P; Almeida, R; Bedbrook, A; Bosnic-Anticevich, S; Brough, HA; Brussino, L; Cardona, V; Casale, T; Cecchi, L; Charpin, D; Chivato, T; Costa, EM; Cruz, AA; Dramburg, S; Durham, SR; De Feo, G; van Wijk, RG; Fokkens, WJ; Gemicioglu, B; Haahtela, T; Illario, M; Ivancevich, JC; Kvedariene, V; Kuna, P; Larenas-Linnemann, DE; Makris, M; Mathieu-Dupas, E; Melén, E; Morais-Almeida, M; Mösges, R; Mullol, J; Nadeau, KC; Nhan, PH; O'Hehir, R; Regateiro, FS; Reitsma, S; Samolinski, B; Sheikh, A; Stellato, C; Todo-Bom, A; Tomazic, PV; Toppila-Salmi, S; Valero, A; Valiulis, A; Ventura, MT; Wallace, D; Waserman, S; Yorgancioglu, A; Vries, G; Eerd, M; Zieglmayer, P; Zuberbier, T; Pfaar, O; Fonseca, JA; Bousquet, J
    Background Validated combined symptom-medication scores (CSMSs) are needed to investigate the effects of allergic rhinitis treatments. This study aimed to use real-life data from the MASK-air(R) app to generate and validate hypothesis- and data-driven CSMSs. Methods We used MASK-air(R) data to assess the concurrent validity, test-retest reliability and responsiveness of one hypothesis-driven CSMS (modified CSMS: mCSMS), one mixed hypothesis- and data-driven score (mixed score), and several data-driven CSMSs. The latter were generated with MASK-air(R) data following cluster analysis and regression models or factor analysis. These CSMSs were compared with scales measuring (i) the impact of rhinitis on work productivity (visual analogue scale [VAS] of work of MASK-air(R), and Work Productivity and Activity Impairment: Allergy Specific [WPAI-AS]), (ii) quality-of-life (EQ-5D VAS) and (iii) control of allergic diseases (Control of Allergic Rhinitis and Asthma Test [CARAT]). Results We assessed 317,176 days of MASK-air(R) use from 17,780 users aged 16-90 years, in 25 countries. The mCSMS and the factor analyses-based CSMSs displayed poorer validity and responsiveness compared to the remaining CSMSs. The latter displayed moderate-to-strong correlations with the tested comparators, high test-retest reliability and moderate-to-large responsiveness. Among data-driven CSMSs, a better performance was observed for cluster analyses-based CSMSs. High accuracy (capacity of discriminating different levels of rhinitis control) was observed for the latter (AUC-ROC = 0.904) and for the mixed CSMS (AUC-ROC = 0.820). Conclusion The mixed CSMS and the cluster-based CSMSs presented medium-high validity, reliability and accuracy, rendering them as candidates for primary endpoints in future rhinitis trials.
  • No Thumbnail Available
    Item
    Real-world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities
    Sousa-Pinto, B; Anto, A; Berger, M; Dramburg, S; Pfaar, O; Klimek, L; Jutel, M; Czarlewski, W; Bedbrook, A; Valiulis, A; Agache, I; Amaral, R; Ansotegui, IJ; Bastl, K; Berger, U; Bergmann, KC; Bosnic-Anticevich, S; Braido, F; Brussino, L; Cardona, V; Casale, T; Canonica, GW; Cecchi, L; Charpin, D; Chivato, T; Chu, DK; Cingi, C; Costa, EM; Cruz, AA; Devillier, P; Durham, SR; Ebisawa, M; Fiocchi, A; Fokkens, WJ; Gemicioglu, B; Gotua, M; Guzmán, MA; Haahtela, T; Ivancevich, JC; Kuna, P; Kaidashev, I; Khaitov, M; Kvedariene, V; Larenas-Linnemann, DE; Lipworth, B; Laune, D; Matricardi, PM; Morais-Almeida, M; Mullol, J; Naclerio, R; Neffen, H; Nekam, K; Niedoszytko, M; Okamoto, Y; Papadopoulos, NG; Park, HS; Passalacqua, G; Patella, V; Pelosi, S; Nhan, PT; Popov, TA; Regateiro, FS; Reitsma, S; Rodriguez-Gonzales, M; Rosario, N; Rouadi, PW; Samolinski, B; Sá-Sousa, A; Sastre, J; Sheikh, A; Ulrik, CS; Taborda-Barata, L; Todo-Bom, A; Tomazic, PV; Toppila-Salmi, S; Tripodi, S; Tsiligianni, I; Valovirta, E; Ventura, MT; Valero, AA; Vieira, RJ; Wallace, D; Waserman, S; Williams, S; Yorgancioglu, A; Zhang, L; Zidarn, M; Zuberbier, J; Olze, H; Antó, JM; Zuberbier, T; Fonseca, JA; Bousquet, J
    Digital health is an umbrella term which encompasses eHealth and benefits from areas such as advanced computer sciences. eHealth includes mHealth apps, which offer the potential to redesign aspects of healthcare delivery. The capacity of apps to collect large amounts of longitudinal, real-time, real-world data enables the progression of biomedical knowledge. Apps for rhinitis and rhinosinusitis were searched for in the Google Play and Apple App stores, via an automatic market research tool recently developed using JavaScript. Over 1500 apps for allergic rhinitis and rhinosinusitis were identified, some dealing with multimorbidity. However, only six apps for rhinitis (AirRater, AllergyMonitor, AllerSearch, Husteblume, MASK-air and Pollen App) and one for rhinosinusitis (Galenus Health) have so far published results in the scientific literature. These apps were reviewed for their validation, discovery of novel allergy phenotypes, optimisation of identifying the pollen season, novel approaches in diagnosis and management (pharmacotherapy and allergen immunotherapy) as well as adherence to treatment. Published evidence demonstrates the potential of mobile health apps to advance in the characterisation, diagnosis and management of rhinitis and rhinosinusitis patients.